Menu
Search
|

Menu

Close
X

Horizon Therapeutics PLC HZNP.OQ (NASDAQ Stock Exchange Global Select Market)

26.34 USD
-0.09 (-0.34%)
As of Sep 13
Previous Close 26.43
Open 26.42
Volume 533,623
3m Avg Volume 634,774
Today’s High 26.66
Today’s Low 26.05
52 Week High 29.44
52 Week Low 16.57
Shares Outstanding (mil) 184.88
Market Capitalization (mil) 4,568.48
Forward P/E 317.28
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
280
FY18
1,208
FY17
1,056
FY16
981
EPS (USD)
FY19
-0.190
FY18
-0.635
FY17
-2.922
FY16
-1.030
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
317.28
33.85
Price to Sales (TTM)
vs sector
3.61
7.90
Price to Book (MRQ)
vs sector
3.04
4.38
Price to Cash Flow (TTM)
vs sector
16.39
23.70
Total Debt to Equity (MRQ)
vs sector
106.92
17.64
LT Debt to Equity (MRQ)
vs sector
90.30
12.61
Return on Investment (TTM)
vs sector
0.41
12.69
Return on Equity (TTM)
vs sector
1.09
17.13

EXECUTIVE LEADERSHIP

Timothy Walbert
Chairman of the Board, President, Chief Executive Officer, Since 2010
Salary: $1,033,330.00
Bonus: $1,167,650.00
Paul Hoelscher
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $541,667.00
Bonus: $319,110.00
Irina Konstantinovsky
Chief Human Resource Officer, Executive Vice President, Since 2017
Salary: $147,538.00
Bonus: $70,471.00
Barry Moze
Executive Vice President, Chief Administrative Officer, Since 2017
Salary: $571,667.00
Bonus: $334,195.00
Shao-Lee Lin
Executive Vice President, Head of Research and Development, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Connaught House
1St Floor, 1 Burlington Road
DUBLIN     4

Phone: +3531.7722100

Horizon Therapeutics PLC, formerly Horizon Pharma Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

SPONSORED STORIES